Ocugen, Inc. (OCGN) Form 8-K — Oct 14, 2026
$OCGNForm 8-KItems 1.01, 7.01, 8.01, 9.01Filed Oct 14, 2026, 9:22 PM ET0001104659-26-115921Original filing
Ocugen (NASDAQ: OCGN) signed an exclusive license agreement on October 13, 2026 granting Roots Pharmaceutical rights to commercialize OCU400, its modifier gene therapy for retinitis pigmentosa, across the Middle East and North Africa. Under the deal, Ocugen receives an upfront license fee and development milestones of up to $4 million, sales milestones of up to $255 million, and 22% royalties on MENA net sales, while also manufacturing commercial supply under a related supply agreement.
Key figures
- Royalty rate
- 22% of net sales
- New record date
- October 30, 2026
- Sales milestones
- up to $255.0 million
- Ocu400 phase3 readout
- Q1 2027 (liMeliGhT trial)
- Special meeting postponed to
- December 22, 2026
- Authorized share increase proposal
- 250,000,000 shares
- Upfront and development milestones
- up to $4 million
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.